Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age ≥ 70 Yrs) With Good Performance Status (PS < 2)
Status: Enrolling
Updated:  8/11/2016
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age ≥ 70 Yrs) With Good Performance Status (PS < 2)
Status: Enrolling
Updated: 8/11/2016
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
Status: Enrolling
Updated:  8/15/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
Status: Enrolling
Updated: 8/15/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  8/15/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 8/15/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With "Acquired Resistance" to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Status: Enrolling
Updated:  8/15/2016
Georgetown University Medical Center
mi
from
Washington,
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With "Acquired Resistance" to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Status: Enrolling
Updated: 8/15/2016
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With "Acquired Resistance" to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Status: Enrolling
Updated:  8/15/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With "Acquired Resistance" to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Status: Enrolling
Updated: 8/15/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/16/2016
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
mi
from
Tampa, FL
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/16/2016
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/16/2016
University of Michigan Comprehensive Cancer Center SC
mi
from
Ann Arbor, MI
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/16/2016
University of Michigan Comprehensive Cancer Center SC
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/16/2016
Karmanos Cancer Institute Dept of Onc
mi
from
Detroit, MI
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/16/2016
Karmanos Cancer Institute Dept of Onc
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/16/2016
Washington University School of Medicine Onc Dept
mi
from
St. Louis, MO
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/16/2016
Washington University School of Medicine Onc Dept
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/16/2016
Memorial Sloan Kettering Cancer Center Onc. Dept
mi
from
NY, NY
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/16/2016
Memorial Sloan Kettering Cancer Center Onc. Dept
mi
from
NY, NY
Click here to add this to my saved trials
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/16/2016
Vanderbilt University Medical Center Dept of Onc
mi
from
Nashville, TN
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/16/2016
Vanderbilt University Medical Center Dept of Onc
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/16/2016
Cancer Therapy & Research Center / UT Health Science Center SC
mi
from
San Antonio, TX
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/16/2016
Cancer Therapy & Research Center / UT Health Science Center SC
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated:  8/16/2016
Novartis Investigative Site
mi
from
Parkville,
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Status: Enrolling
Updated: 8/16/2016
Novartis Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
An Open-Label Phase 1b Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
Status: Enrolling
Updated:  8/16/2016
Virginia G. Piper Cancer Center
mi
from
Scottsdale, AZ
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
An Open-Label Phase 1b Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
Status: Enrolling
Updated: 8/16/2016
Virginia G. Piper Cancer Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
An Open-Label Phase 1b Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
Status: Enrolling
Updated:  8/16/2016
Sarcoma Oncology Center
mi
from
Santa Monica, CA
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
An Open-Label Phase 1b Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
Status: Enrolling
Updated: 8/16/2016
Sarcoma Oncology Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Medical Center of Aurora
mi
from
Aurora, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Medical Center of Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Boulder Community Hospital
mi
from
Boulder, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Rose Medical Center
mi
from
Denver, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Porter Adventist Hospital
mi
from
Denver, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Swedish Medical Center
mi
from
Englewood, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Saint Mary's Hospital and Regional Medical Center
mi
from
Grand Junction, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Saint Mary's Hospital and Regional Medical Center
mi
from
Grand Junction, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
North Colorado Medical Center
mi
from
Greeley, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
North Colorado Medical Center
mi
from
Greeley, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Littleton Adventist Hospital
mi
from
Littleton, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Littleton Adventist Hospital
mi
from
Littleton, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Longmont United Hospital
mi
from
Longmont, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Longmont United Hospital
mi
from
Longmont, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
McKee Medical Center
mi
from
Loveland, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
McKee Medical Center
mi
from
Loveland, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Parker Adventist Hospital
mi
from
Parker, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Parker Adventist Hospital
mi
from
Parker, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
St. Mary - Corwin Medical Center
mi
from
Pueblo, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
St. Mary - Corwin Medical Center
mi
from
Pueblo, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
North Suburban Medical Center
mi
from
Thornton, CO
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
North Suburban Medical Center
mi
from
Thornton, CO
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Manchester Memorial Hospital
mi
from
Manchester, CT
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Manchester Memorial Hospital
mi
from
Manchester, CT
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Eastern Connecticut Hematology and Oncology Associates
mi
from
Norwich, CT
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Eastern Connecticut Hematology and Oncology Associates
mi
from
Norwich, CT
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Sibley Memorial Hospital
mi
from
Washington,
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Sibley Memorial Hospital
mi
from
Washington,
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
University of Florida
mi
from
Gainesville, FL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Rush - Copley Medical Center
mi
from
Aurora, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Rush - Copley Medical Center
mi
from
Aurora, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Graham Hospital Association
mi
from
Canton, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Graham Hospital Association
mi
from
Canton, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Memorial Hospital
mi
from
Carthage, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Decatur Memorial Hospital
mi
from
Decatur, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Eureka Hospital
mi
from
Eureka, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Eureka Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Mason District Hospital
mi
from
Havana, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Hinsdale Hematology Oncology Associates Incorporated
mi
from
Hinsdale, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Hinsdale Hematology Oncology Associates Incorporated
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Joliet Oncology-Hematology Associates Limited
mi
from
Joliet, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Joliet Oncology-Hematology Associates Limited
mi
from
Joliet, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
McDonough District Hospital
mi
from
Macomb, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
BroMenn Regional Medical Center
mi
from
Normal, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Pekin Hospital
mi
from
Pekin, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Pekin Hospital
mi
from
Pekin, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Proctor Hospital
mi
from
Peoria, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/18/2016
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/18/2016
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials